Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received an average rating of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of analysts recently weighed in on SANA shares. Morgan Stanley reiterated an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a research note on Friday, March 13th. HC Wainwright reduced their target price on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Rodman & Renshaw assumed coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 target price for the company. Wedbush raised their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Finally, Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st.

Sana Biotechnology Trading Up 2.0%

SANA stock opened at $3.56 on Thursday. The company has a market capitalization of $990.71 million, a P/E ratio of -3.83 and a beta of 2.13. Sana Biotechnology has a twelve month low of $2.61 and a twelve month high of $6.55. The business has a 50 day simple moving average of $3.20 and a 200-day simple moving average of $3.68.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. Research analysts predict that Sana Biotechnology will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Xponance LLC increased its holdings in shares of Sana Biotechnology by 25.6% in the fourth quarter. Xponance LLC now owns 13,068 shares of the company’s stock valued at $53,000 after purchasing an additional 2,662 shares during the period. Creative Planning raised its stake in shares of Sana Biotechnology by 5.3% during the third quarter. Creative Planning now owns 54,177 shares of the company’s stock worth $192,000 after purchasing an additional 2,719 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Sana Biotechnology by 29.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock worth $53,000 after purchasing an additional 2,943 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in shares of Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares during the period. Finally, Polymer Capital Management US LLC grew its position in Sana Biotechnology by 32.5% in the 4th quarter. Polymer Capital Management US LLC now owns 18,285 shares of the company’s stock valued at $74,000 after buying an additional 4,480 shares during the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.